Gilead invests $5 billion to deepen ties with biotech Galapagos
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Gilead invests $5 billion to deepen ties with biotech Galapagos
July 15, 2019 7:30 AM EDT
H.C. Wainwright analyst Debjit Chattopadhyay raised the price target on Galapagos NV (NASDAQ: GLPG) to $205.00 (from $105.00) while maintaining a Buy rating.
The analyst commented, "Having missed the acquisition boat, Gilead (GILD; not rated) forks up billions to shore up and diversify its pipeline. Given GIlead's internal issues, management overhaul, the unknowns heading into the FINCH Phase 3 readouts, and the questionable valuation for its last M&A foray, it is no surprise the team was gun shy from an M&A perspective. With the $5.1B R&D collaboration announced on July 14,... More
July 15, 2019 6:52 AM EDT
Cantor Fitzgerald analyst Eliana Merle raised the price target on Galapagos NV (NASDAQ: GLPG) to $188.00 (from $130.00) while maintaining an Overweight rating, saying the transformative Gilead deal sets stage for building next pillars of growth.
Merle commented, "We think this historic... More
July 15, 2019 3:11 AM EDT
Citi analyst Nick Nieland reiterated a Buy rating and EUR140.00 price target on Galapagos NV (GLPG:NA) (NASDAQ: GLPG).
The analyst comments ..."the investment from Gilead de-risks the Galapagos story and is a significant step towards establishing itself as an independent... More
